Roswell Park Cancer Institute
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Roswell Park Cancer Institute sits in the top decile of US sponsors by registered trial count (#98 of 15,742 sponsors by registered trial count).
Roswell Park Cancer Institute: 365 sponsored US clinical trials, 57 recruiting.
Roswell Park Cancer Institute sponsors 365 registered US clinical trials on ClinicalTrials.gov, 57 of them currently recruiting, and 200 completed. 7 of these trials are in Phase 3-4 (later-stage) and 238 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Leukemia, with 9 trials.
Top-decile sponsor footprint
Roswell Park Cancer Institute ranks in the top decile of sponsors by registered trial count (#98 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
200 of 279 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (71.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
365 total, page 7 of 8
Photodynamic Therapy in Treating Patients With Precancerous Esophageal Conditions or Early Stage Esophageal Cancer
NCT00281736
Photodynamic Therapy in Treating Patients With Lung Cancer
NCT01668823
Capecitabine, Oxaliplatin, and Gefitinib in Treating Patients With Metastatic Colorectal Cancer
NCT00087334
Donor Lymphocyte Infusion in Treating Patients With Recurrent or Persistent Hematologic Cancer After Donor Stem Cell Transplant
NCT00534118
Oxaliplatin, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Rectum
NCT00086931
Oxaliplatin, Gefitinib, and Radiation Therapy in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer
NCT00093652
Study To Determine The Maximum Range of Light Doses At Two HPPH Doses With Acceptable Normal Tissue Toxicity For PDT Treatment Of High Grade Dysplasia,CIS or Early Adenocarcinoma In Barrett's Esophagus
NCT01238042
Donor Umbilical Cord Blood Transplantation in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders
NCT00055653
Irinotecan and Capecitabine in Treating Women With Advanced Breast Cancer
NCT00083148
Calcitriol and Gefitinib With or Without Dexamethasone in Treating Patients With Advanced Solid Tumors
NCT00084708
Gemcitabine and Capecitabine in Treating Patients With Advanced and/or Inoperable Cholangiocarcinoma or Carcinoma of the Gallbladder
NCT00084942
Calcitriol and Dexamethasone Before Radical Prostatectomy in Treating Patients With Localized Adenocarcinoma (Cancer) of the Prostate
NCT00084864
Interleukin-2 and Stem Cell Factor in Treating Patients With AIDS or AIDS-Related Cancer
NCT00058045
Sargramostim in Reducing Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplantation for Hematologic Cancer or Aplastic Anemia
NCT00053157
Docetaxel, Capecitabine, and Cisplatin in Treating Patients With Advanced Solid Tumors
NCT00084734
Fludarabine and Thalidomide in Treating Patients With Newly Diagnosed Chronic Lymphocytic Leukemia
NCT00096018
Arsenic Trioxide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia
NCT00093483
Calcitriol and Dexamethasone in Treating Patients With Prostate Cancer Who Have Undergone Surgery or Radiation Therapy
NCT00054522
Chemotherapy and Stem Cell Transplantation in Treating Children With Central Nervous System Cancer
NCT00053118
NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders
NCT00053989
Oxaliplatin in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer
NCT00040820
S-3304 in Treating Patients With Advanced Solid Tumors
NCT00033566
Photodynamic Therapy Using Porfimer Sodium in Treating Patients With Recurrent Mouth or Throat Dysplasia or Recurrent In Situ Cancer or Stage I Cancer of the Mouth or Throat
NCT00530088
Thalidomide in Treating Anemia in Patients With Myelodysplastic Syndrome
NCT00030550
Irinotecan and Gemcitabine in Treating Patients With Refractory Advanced Solid Tumors
NCT00054288
Photodynamic Therapy With HPPH in Treating Patients With Non-Small Cell Lung Cancer
NCT00025571
Irinotecan Followed by Fluorouracil in Treating Patients With Advanced Solid Tumors
NCT00024141
Compassionate Use of Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Gastrointestinal Tract
NCT00055666
Vaccine Therapy in Treating Patients With Non-Small Cell Lung Cancer
NCT00023985
Vaccine Therapy in Preventing Flu in Children With Acute Lymphoblastic Leukemia
NCT00022035
Study of Photodynamic Therapy (PDT) Using HPPH in Barrett's Esophagus
NCT01236443
Genetic Changes in Patients With Non-Small Cell Lung Cancer Who Are Receiving Vinorelbine and Gemcitabine Before Surgery
NCT00057798
Photodynamic Therapy in Treating Patients With Basal Cell Skin Cancer
NCT00017485
Irinotecan and Cytarabine in Treating Patients With Refractory or Recurrent Acute Myeloid Leukemia or Chronic Myelogenous Leukemia
NCT00053144
Doxorubicin and Interleukin-2 in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
NCT00004248
BCG Plus Interferon Alfa 2b in Treating Patients With Bladder Cancer
NCT00004122
Thalidomide in Treating Patients With Chronic Graft-Versus-Host Disease Following Bone Marrow Transplant
NCT00003894
Anhydrovinblastine in Treating Patients With Advanced Recurrent Solid Tumors
NCT00003882
Surgery and Photodynamic Therapy in Treating Patients With Malignant Mesothelioma
NCT00054002
Photodynamic Therapy in Treating Patients With Lymphoma or Chronic Lymphocytic Leukemia
NCT00054171
Glutamine in Treating Side Effects in Children Who Are Undergoing Stem Cell Transplantation
NCT00003898
Combination Chemotherapy Followed By Filgrastim or Sargramostim in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
NCT00053131
Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer
NCT00003816
Peripheral Stem Cell Transplantation With or Without Stromagen Following Chemotherapy in Treating Women With Metastatic Breast Cancer
NCT00003877
Phase III Randomized Study of Cyclophosphamide With or Without Antithymocyte Globulin Before Bone Marrow Transplantation in Patients With Aplastic Anemia
NCT00004474
Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Other Hematologic or Metabolic Diseases
NCT00003662
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
NCT00003661
Dimesna in Treating Patients With Solid Tumors Who Are Undergoing Treatment With Cisplatin and Paclitaxel
NCT00003569
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
NCT00003270
Vaccine Therapy in Treating Patients With Stage I, Stage II, or Stage IIIA Non-small Cell Lung Cancer or With Stage I or Stage II Mesothelioma
NCT00003974
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 123 |
| Phase 2 | 115 |
| Phase 3 | 5 |
| Phase 4 | 2 |
What is open in the Roswell Park Cancer Institute pipeline
57 recruiting of 365 indexed (16% open); 200 completed (55%).
Phase mix: 7 late (III/IV) vs 238 early (I/II) (early-phase heavy).
Top condition: Leukemia (9 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Roswell Park Cancer Institute: open-pipeline peers nationwide
Peers matched on 365 registered trials and 16% open enrollment, not the therapeutic-area sidebar.
Roswell Park Cancer Institute sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 365 trials (± recruiting share)
- UNC Lineberger Comprehensive Cancer Center · 366 trials · 22% recruiting
- New York State Psychiatric Institute · 364 trials · 3% recruiting
- University of California, Irvine · 368 trials · 20% recruiting
- Northwell Health · 370 trials · 22% recruiting
Sponsors near 16% open enrollment (± trial volume)
- Cambridge Health Alliance · 16% recruiting · 45 trials
- Louisiana State University Health Sciences Center in New Orleans · 16% recruiting · 45 trials
- University of Southern California · 16% recruiting · 617 trials
- Incyte Corporation · 15% recruiting · 239 trials
Related
What to do with this Roswell Park Cancer Institute page
365 registered trials is a research-attention snapshot, not an endorsement of Roswell Park Cancer Institute or any single study.
- 57 of Roswell Park Cancer Institute's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Leukemia is the condition Roswell Park Cancer Institute studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Leukemia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Roswell Park Cancer Institute pipeline card: 365 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.